Results 1 to 10 of about 463,157 (302)

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity [PDF]

Cells, 2022
Current research proves that immune dysregulation is a common feature of coronavirus disease 2019 (COVID-19), and immune exhaustion is associated with increased disease mortality.
Paulina Niedźwiedzka-Rystwej, Adam Majchrzak, Bogusz Aksak-Wąs, Karol Serwin, Zenon Czajkowski, Ewelina Grywalska, Izabela Korona-Głowniak, Jacek Roliński, Miłosz Parczewski   +8 more
doaj   +4 more sources

Immunotherapy With Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors in Patients With Advanced Non–Small Cell Lung Cancers: A Multicenter, Retrospective Analysis [PDF]

MedComm
This multicenter retrospective study analyzed data from 1266 patients with advanced non–small cell lung cancer (NSCLC) across five leading hospitals in China. The aim was to evaluate survival outcomes and safety profiles of programmed cell death 1 (PD‐1)
Jiadi Gan, Kaixin Lei, Tao Chang, Juan Wang, Ruiyuan Yang, Quanling Kong, Jingyi Yuan, Wenjun Meng, Yalun Li, Lina He, Jiaoming Li, Zeng Yan, Bojiang Chen, Weimin Li   +13 more
doaj   +2 more sources

The Role of Programmed Cell Death 1/Programmed Death Ligand 1 (PD-1/PD-L1) Axis in Sepsis-Induced Apoptosis [PDF]

Medicina
Background and Objectives: Sepsis involves a dysregulated host response, characterized by simultaneous immunosuppression and hyperinflammation. Initially, there is the release of pro-inflammatory factors and immune system dysfunction, followed by ...
Oana Coman, Bianca-Liana Grigorescu, Adina Huțanu, Anca Bacârea, Anca Meda Văsieșiu, Raluca Ștefania Fodor, Florin Stoica, Leonard Azamfirei   +7 more
doaj   +2 more sources

Expression of PD-1 and PD-L1 in Breast Carcinoma: Research Protocol for a Cohort Study [PDF]

Journal of Clinical and Diagnostic Research, 2023
Introduction: Breast cancer is the most common malignant tumour and the leading cause of cancer-related death in women is breast cancer. The Immunohistochemistry (IHC) method utilised antigens and antibodies to interact to identify cellular or tissue
Shreya Ghosh, Jayant S Makarande, Sunita Vagha, Anil K Agrawal, Sahitya Vodithala   +4 more
doaj   +1 more source

An update on immunotherapy with PD-1 and PD-L1 blockade [PDF]

Yeungnam University Journal of Medicine, 2021
Cancer is the leading cause of death and is on the rise worldwide. Until 2010, the development of targeted treatment was mainly focused on the growth mechanisms of cancer.
Sung Ae Koh
doaj   +1 more source

PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients [PDF]

Journal of Pathology and Translational Medicine, 2017
Background Programmed death ligand 1 (PD-L1) in tumor cells is known to promote immune escape of cancer by interacting with programmed cell death 1 (PD-1) in tumor infiltrating immune cells.
Jiheun Han, Yongkil Hong, Youn Soo Lee
doaj   +1 more source

Programmed Cell Death Protein 1 Inhibitor-Mediated Peripheral Neuropathy

JTO Clinical and Research Reports, 2023
The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the model of antitumor therapy. With the continuous deepening of the research on the mechanism of immunotherapy, ICIs, such as programmed cell death protein 1 (PD-1), programmed ...
Yanyun Ao, BA, Ming Gao, MM, Binbin Sun, MD, Hongjun Hao, PhD, Huan Yan, MM, Chuntong Li, MD, Decong Sun, MD, Xuejiao Yang, BA, Yanfang Ju, MD, Xia Zhang, MD, Junxun Ma, MD   +10 more
doaj   +1 more source

Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report

BMC Pulmonary Medicine, 2021
Background Immune checkpoint inhibitors have potential applications in treating various cancers but are associated with immune-related adverse events, such as inflammation, in a wide range of organs; however, allergic inflammation caused by these agents ...
Masanori Harada, Hyogo Naoi, Kazuyo Yasuda, Yutaro Ito, Namio Kagoo, Tsutomu Kubota, Koshiro Ichijo, Eisuke Mochizuki, Masahiro Uehara, Shun Matsuura, Masaru Tsukui, Naoki Koshimizu   +11 more
doaj   +1 more source

Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients

Indian Journal of Rheumatology, 2022
Background: Programmed cell death 1(PD-1)/programmed cell death ligand 1 (PD-L1) pathway is an immune checkpoint implicated in immune tolerance and involved in the pathogenesis of several autoimmune diseases.
Eman Eissa, Rania Kandil, Nehal El-Ghobashy, Walaa Abdelfattah, Zainab Hammouda, Sara Medhat Gadelsayed, Faten Bayoumi   +6 more
doaj   +1 more source

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1

Chinese Medical Journal, 2020
. Historically, breast cancer has been regarded as an immunogenic “cold” tumor. However, the discovery of immune checkpoint inhibitors has made immunotherapy becoming an emerging new treatment modality for breast cancer.
Jing Zhao, Jian Huang, Qiang Shi
doaj   +1 more source